Kidney Transplant Rejection-Pipeline Review, H1 2017

Kidney Transplant Rejection-Pipeline Review, H1 2017


  • Products Id :- GMDHC9247IDB
  • |
  • Pages: 148
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Kidney Transplant Rejection-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection-Pipeline Review, H1 2017, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).

The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Kidney Transplant Rejection-Overview 7

Kidney Transplant Rejection-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Kidney Transplant Rejection-Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Kidney Transplant Rejection-Companies Involved in Therapeutics Development 24

Amgen Inc 24

Angion Biomedica Corp 24

Apellis Pharmaceuticals Inc 25

Astellas Pharma Inc 25

Biogen Inc 26

Catalyst Biosciences Inc 26

Corline Biomedical AB 27

CSL Ltd 27

GlaxoSmithKline Plc 28

Grifols SA 28

Hansa Medical AB 29

Kyowa Hakko Kirin Co Ltd 29

Magnus Life Ltd 30

Noorik Biopharmaceuticals AG 30

Novartis AG 31

Opsona Therapeutics Ltd 31

OSE Immunotherapeutics 32

Pharmicell Co Ltd 32

Pharming Group NV 33

Prolong Pharmaceuticals LLC 33

Quark Pharmaceuticals Inc 34

Shire Plc 34

Tiziana Life Sciences Plc 35

Kidney Transplant Rejection-Drug Profiles 36

albumin (human)-Drug Profile 36

ambrisentan-Drug Profile 37

AMY-101-Drug Profile 38

APL-2-Drug Profile 40

AS-2521780-Drug Profile 43

ASP-0028-Drug Profile 44

basiliximab biobetter-Drug Profile 45

BB-3-Drug Profile 46

belimumab-Drug Profile 50

bleselumab-Drug Profile 57

C1 esterase inhibitor (human)-Drug Profile 59

C1 esterase inhibitor (human)-Drug Profile 64

C1 esterase inhibitor (recombinant)-Drug Profile 67

carfilzomib-Drug Profile 74

CB-2782-Drug Profile 86

Cellgram for Kidney Transplant Rejection-Drug Profile 87

Cellular Immunotherapy for Kidney Transplantation-Drug Profile 88

Cellular Immunotherapy for Kidney Transplantation-Drug Profile 89

Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation-Drug Profile 90

CFZ-533-Drug Profile 91

foralumab-Drug Profile 93

FR-104-Drug Profile 95

FX-06-Drug Profile 98

GSK-1070806-Drug Profile 100

HBI-002-Drug Profile 101

HBI-137-Drug Profile 102

lefluonomide-Drug Profile 103

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology-Drug Profile 104

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation-Drug Profile 106

MRX-109-Drug Profile 107

OPN-305-Drug Profile 108

QPI-1002-Drug Profile 111

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders-Drug Profile 114

Renaparin-Drug Profile 119

rituximab-Drug Profile 120

Sanguinate-Drug Profile 126

tiomolibdate diammonium-Drug Profile 129

TNT-009-Drug Profile 130

Kidney Transplant Rejection-Dormant Projects 133

Kidney Transplant Rejection-Discontinued Products 135

Kidney Transplant Rejection-Product Development Milestones 136

Featured News & Press Releases 136

Appendix 145

Methodology 145

Coverage 145

Secondary Research 145

Primary Research 145

Expert Panel Validation 145

Contact Us 145

Disclaimer 146

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kidney Transplant Rejection-Pipeline by Amgen Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Angion Biomedica Corp, H1 2017

Kidney Transplant Rejection-Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Astellas Pharma Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Biogen Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Catalyst Biosciences Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Corline Biomedical AB, H1 2017

Kidney Transplant Rejection-Pipeline by CSL Ltd, H1 2017

Kidney Transplant Rejection-Pipeline by GlaxoSmithKline Plc, H1 2017

Kidney Transplant Rejection-Pipeline by Grifols SA, H1 2017

Kidney Transplant Rejection-Pipeline by Hansa Medical AB, H1 2017

Kidney Transplant Rejection-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Kidney Transplant Rejection-Pipeline by Magnus Life Ltd, H1 2017

Kidney Transplant Rejection-Pipeline by Noorik Biopharmaceuticals AG, H1 2017

Kidney Transplant Rejection-Pipeline by Novartis AG, H1 2017

Kidney Transplant Rejection-Pipeline by Opsona Therapeutics Ltd, H1 2017

Kidney Transplant Rejection-Pipeline by OSE Immunotherapeutics, H1 2017

Kidney Transplant Rejection-Pipeline by Pharmicell Co Ltd, H1 2017

Kidney Transplant Rejection-Pipeline by Pharming Group NV, H1 2017

Kidney Transplant Rejection-Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Kidney Transplant Rejection-Pipeline by Quark Pharmaceuticals Inc, H1 2017

Kidney Transplant Rejection-Pipeline by Shire Plc, H1 2017

Kidney Transplant Rejection-Pipeline by Tiziana Life Sciences Plc, H1 2017

Kidney Transplant Rejection-Dormant Projects, H1 2017

Kidney Transplant Rejection-Dormant Projects, H1 2017 (Contd..1), H1 2017

Kidney Transplant Rejection-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc, Angion Biomedica Corp, Apellis Pharmaceuticals Inc, Astellas Pharma Inc, Biogen Inc, Catalyst Biosciences Inc, Corline Biomedical AB, CSL Ltd, GlaxoSmithKline Plc, Grifols SA, Hansa Medical AB, Kyowa Hakko Kirin Co Ltd, Magnus Life Ltd, Noorik Biopharmaceuticals AG, Novartis AG, Opsona Therapeutics Ltd, OSE Immunotherapeutics, Pharmicell Co Ltd, Pharming Group NV, Prolong Pharmaceuticals LLC, Quark Pharmaceuticals Inc, Shire Plc, Tiziana Life Sciences Plc

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com